Thema: IL0011050551
EVGN, IL0011050551
stock-6682491_1920.jpg - Foto: THN
Evogene stock: AI program targets acute graft-versus-host disease
Evogene stock is gaining a new internal drug-discovery focus in acute graft-versus-host disease. The program is moving toward lead optimization and IND-enabling work.
ad-hoc-news.de, heute 00:36 Uhr
EVGN, IL0011050551
Evogene stock: Evogene announces AI roadshow. November 2 ...
Evogene will present ChemPass AI from November 2-5, 2026. The November 10 shareholder vote also matters for Evogene stock.
ad-hoc-news.de, 23.10.26 03:36 Uhr
EVGN, IL0011050551
Evogene stock: Evogene joins AI roadshow. Evogene stock ...
Evogene will meet U.S. investors November 2-5, 2026. For Evogene stock, Nasdaq's USD 1.00 rule runs to March 29, 2027.
ad-hoc-news.de, 22.10.26 06:44 Uhr
EVGN, IL0011050551
Evogene reaches board deal: what it means for Evogene stock ...
The pact sets seven directors and a 60-day standstill. Evogene stock stood at USD 0.39 on October 13, 2026 versus USD 1.00 Nasdaq minimum.
ad-hoc-news.de, 14.10.26 06:15 Uhr
